



BC Centre for Disease Control
Provincial Health Services Authority

Immunization Programs and Vaccine Preventable
Diseases Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515

www.bccdc.ca

Communicable Disease Control Manual

Chapter 2: Immunization

Part 5 – Adverse Events Following Immunization

Table of Contents

1. Introduction	4
2. Purpose	4
3. Reporting Adverse Events	4
3.1 Freedom of Information and Protection of Privacy (FOI/PP).....	5
4. Adverse Event Monitoring Information Flow	6
5. Recommendations Following an Adverse Event	6
5.1 Pediatric Vaccine Consultation Service.....	7
6. Summary of Reporting Criteria.....	8
7. Local Reactions at Injection Site.....	12
7.1 Abscesses at Injection Site.....	12
7.2 Cellulitis.....	13
7.3 Nodule.....	13
7.4 Pain, Redness and Swelling	14
8. Systemic Reactions.....	15
8.1 Adenopathy/Lymphadenopathy	15
8.2 Fever	15
8.3 Hypotonic-Hyporesponsive Episode (HHE).....	16
8.4 Parotitis	17
8.5 Orchitis	17
8.6 Rash.....	18
8.7 Screaming/Persistent crying	19
8.8 Severe Vomiting/Diarrhea	19
9. Allergic Reactions	20
9.1 Anaphylaxis.....	20
9.2 Oculo-respiratory Syndrome (ORS)	21
9.3 Other Allergic Reactions	22
10. Neurological Events	23

10.1	Anaesthesia/Paraesthesia	23
10.2	Bell’s Palsy	24
10.3	Convulsion/Seizure	24
10.4	Encephalopathy/Encephalitis, Myelitis/Transverse Myelitis, ADEM and SSPE ...	25
10.4.1	Encephalopathy/Encephalitis.....	25
10.4.2	Myelitis/Transverse Myelitis	26
10.4.3	Acute Disseminated Encephalomyelitis (ADEM)	27
10.4.4	Subacute Sclerosing Panencephalitis (SSPE)	27
10.5	Guillain-Barré syndrome (GBS)	28
10.6	Meningitis.....	29
10.7	Vaccine Associated Paralytic Poliomyelitis.....	29
11.	Other Events of Interest.....	30
11.1	Arthritis	30
11.2	Kawasaki Disease	31
11.3	Intussusception/Hematochezia.....	31
11.4	Syncope with Injury	32
11.5	Thrombocytopenia	33
11.6	Thrombosis and Thromboembolism	34
11.7	Myocarditis and/or Pericarditis.....	35
11.8	Other Severe or Unusual Events.....	36
12.	Background on Adverse Event Surveillance.....	36
12.1	Objectives of Surveillance.....	37
12.2	Regional Public Health and Health Authorities	37
12.3	British Columbia Centre for Disease Control (BCCDC)	38
12.4	National Role in Surveillance	38
12.5	International Role in Surveillance.....	39
12.6	Future Directions.....	39

13. Vaccine Injury Support Program.....	40
14. References.....	41

1. Introduction

An adverse event following immunization (AEFI) is any untoward medical occurrence in a vaccinee that follows immunization and does not necessarily have a causal relationship with the vaccine or the immunization process. Temporal association alone (i.e., onset of an event following receipt of vaccine) is not proof of causation.

Vaccine safety is a focus of pre-licensure studies. An acceptable safety profile must be observed in order for vaccines to progress to phase III (clinical) trials in humans. These studies provide frequency data on the occurrence of common adverse events such as local reactions at the injection site or systemic events, and grading of the severity of these events.

Uncommon and rare adverse events are usually not identified in pre-licensure studies and reliance is placed on phase IV studies or post-marketing surveillance; this is especially important in the first year or so following introduction of a vaccine (see [Canadian Immunization Guide, Part 2 – Vaccine Safety](#)).⁽¹⁾

2. Purpose

The purpose of this document is to provide criteria for the reporting of adverse events, and to assist health practitioners who administer vaccines with the interpretation of adverse events following immunization and their implications for subsequent immunization.

3. Reporting Adverse Events

As of January 1, 2019, a health professional who is aware of an adverse event following immunization must report the event to the medical health officer as per the [Reporting Information Affecting Public Health Regulation](#), Part 2, Division 1, Section 5 of the Public Health Act.

Events that **must be reported** include the following (full details in [6. Summary of Reporting Criteria](#)):

- Serious events: life threatening or resulting in death; requiring hospitalization; resulting in a residual disability; associated with congenital malformation.
- Event requiring urgent medical attention.
- Unusual or unexpected events:
 - the event has either not been identified previously [e.g., Oculo-Respiratory Syndrome (ORS) was first identified during the 2000/2001 influenza season], or
 - the event has been identified before but is occurring with greater frequency in the population (e.g., extensive local reactions).
- Clusters of events: known or new events that occur in a geographic or temporal cluster (e.g., 6 in a week, or 6 in a Health Service Delivery Area) that require further assessment, even if the total number of AEFIs may not be higher than expected.
- Note: A causal relationship between receipt of a vaccine(s) and an AEFI does not need to be proven.

Timeframe for reporting (i.e., days between notification of AEFI by the HA and entry into the provincial system)

- Initial case report (in electronic public health system): 5 business days

- Remaining items from the minimum dataset (those requiring interview/follow-up): 60 calendar days
- Additional criteria recommended for immediate provincial reporting to Medical Lead - Immunization Programs and Vaccine Preventable Diseases Service (IPVPDS) at BCCDC:
 - MHO opinion of a cluster of unusual or severe events
 - Death purported to be associated with vaccine

Events that should not be reported:

- Any event which follows immunization that has been clearly attributed to other causes **OR** does not meet reporting criteria (e.g., not serious such as mild vomiting or diarrhea, temporal relationship incompatible with association with vaccine receipt) should not be reported as an AEFI.
- Local injection site reactions and non-specific systemic reactions (e.g., headache, myalgia) should not be reported as AEFI unless these are more frequent or severe than expected based on clinical trial findings (rates and severity are typically found in the product monograph), or based on the judgement of the health care professional familiar with the side effect profile of the particular vaccine(s) based on their experience.

If a client or healthcare provider notifies public health of an event that does not meet AEFI reporting criteria, the event should not be reported in the Adverse Event surveillance module of the public health information system. Such events may be documented in client notes within the public health information system as per health authority guidelines, and the client should be counselled about expected reactions following immunization and how to manage these reactions. If an AEFI report has been initiated in the Adverse Event surveillance module and it is subsequently determined that it does not meet the reporting criteria, set the Status field to “Does not meet reporting criteria”.

The AEFI reporting system is designed for active immunizing products. Completion of the [AEFI Case Report Form](#) will result in a report through the public health information system to the Public Health Agency of Canada. Adverse events following receipt of a passive immunizing agent (e.g., immune globulin) or diagnostic agent (e.g., tuberculin skin test), including in instances where a vaccine is given at the same visit and the adverse event cannot be specifically associated with any given product administered at that visit, should be reported per [Vanessa's Law](#) using the procedures for reporting an adverse drug reaction to the [Canada Vigilance Program](#) using the Side Effect Reporting Form ([online/fillable PDF](#)) at Health Canada. Adverse reactions to medications other than immunizations should be reported in the BC Patient Safety and Learning System (BCPSLS) for those who use the BCPSLS. BCPSLS is a system that collects adverse patient events, including adverse drug reactions, which are reviewed and forwarded to Health Canada on behalf of the health authorities.


Further details on how to report adverse events when both vaccine and tuberculin and/or immunoglobulin have been administered are contained in the [Panorama AEFI Data Entry Guidelines](#).

3.1 Freedom of Information and Protection of Privacy (FOI/PP)

Inform the client that the information is collected under the Public Health Act (in order to monitor the safety of vaccines at the local, provincial and national level), what will be done with it (reported to BCCDC; reported to the Public Health Agency of Canada after removal of personal identifiers; and reported to the client's health care provider), that it will be handled confidentially and not disclosed without authority, and where it will be housed (electronically, on a server maintained by the Provincial Health Services Authority). As well, inform the client of whom to call for more information about FOI issues at the Health Authority (this is a local contact person employed by the HA whose responsibility is ensuring that the HA is in compliance with municipal and provincial FOI/PP legislation).

4. Adverse Event Monitoring Information Flow

Refer to section [12. Background on Adverse Event Surveillance](#) for information on these agencies.



5. Recommendations Following an Adverse Event

Health Authorities may determine a process for assessment and decision-making regarding reported adverse events, and which events assessed by a health care provider will require reviewing by the Medical Health Officer. It is within a Registered Nurse (RN) scope of practice to assess adverse events following immunization and determine a course of action that may include decision-making about subsequent doses of the vaccine(s).

The following are **recommended** criteria for events to be reviewed by the Medical Health Officer:

- events which the client's health care provider considers to confer precautions, contraindications or a reason to postpone a future immunization
- all events managed as anaphylaxis
- all neurological events including febrile and afebrile convulsions

- allergic events
- all events where medical attention is required, and
- all events that are serious (resulting in hospitalization, residual disability, death, or congenital malformation)

Recommendations following adverse event review should be discussed with the client and provided to the client's primary health care provider.

5.1 Pediatric Vaccine Consultation Service

The Family Immunization Clinic (FIC) at BC Children's Hospital provides publicly-funded immunizations to patients at BC Children's and BC Women's Hospital and their friends and family visiting the hospital. The FIC also provides vaccine consultation services to families and health care providers for issues regarding a particular child's immunizations. These consultation services include:

- counselling children and families with unusual or complex illnesses that impact their immunization needs and/or schedule
- assisting in risk-benefit analysis for clients who have had an AEFI to provide advice and guidance for future immunizations
- assisting pediatricians, medical health officers and family physicians with challenging cases to ensure they have a comprehensive immunization plan for a variety of medically compromised children
- providing additional information for families who are vaccine hesitant

Consultation services with the FIC can take place in person or at a distance. For children residing in the lower mainland, consultations are provided as part of routine out-patient services at the FIC. For children residing outside of the lower mainland, consultation services can be provided at a distance via virtual care using a telehealth delivery service. Health care providers can contact the FIC (phone: 604-875-3000) to request a Telehealth consultation at a site local to the client. This is generally a private room in a hospital or public health unit (for a list of local Telehealth sites see: <http://www.phsa.ca/health-professionals/professional-resources/video-conferencing-services/locations>). The Telehealth appointment will be booked for a specific site and at a specific time. At the Telehealth site, the client will be in two-way video communication with the specialist physician (and possibly infectious disease residents). The family physician or MHO may be included in the consultation.

A Travel Assistance Program (TAP) is available for children residing outside of the lower mainland where a distance consultation is not possible. Further information on the TAP can be found at <http://www2.gov.bc.ca/gov/content/health/accessing-health-care/tap-bc/travel-assistance-program-tap-bc>.

For further information about FIC, go to <http://www.bcchildrens.ca/our-services/clinics/family-immunization>.

Contact information:

Family Immunization Clinic
BC Children's Hospital
Ambulatory Care Building
4480 Oak Street

Vancouver BC, V6H 3N1
Phone: 604-875-3000
Fax: 604-875-2311
Email: FamilyImmunizationClinic@cw.bc.ca

6. Summary of Reporting Criteria

For events with reporting criteria for a physician diagnosis, where appropriate and based on current scope of practice, the diagnosis may be made by a Nurse Practitioner.

Adverse Event Following Immunization	Reporting Criteria	Temporal Criteria ^A	
		Inactivated Vaccines	Live Attenuated Vaccines
Local Reaction at Injection Site			
Abscess, Infected	<ul style="list-style-type: none"> Material from abscess known to be purulent (positive gram stain or culture) OR There are one or more signs of localized inflammation (erythema, pain to light touch, warmth) AND <ul style="list-style-type: none"> Evidence of improvement on antimicrobial therapy OR Physician-diagnosed 	0-7 days	
Abscess, Sterile	<ul style="list-style-type: none"> Physician-diagnosed AND any of the following: <ul style="list-style-type: none"> Material from mass is known to be non-purulent Absence of localized inflammation Failure to improve on antimicrobial therapy 	0-7 days	
Cellulitis	<ul style="list-style-type: none"> Physician-diagnosed AND characterized by at least 3 of the following: pain or tenderness to touch, erythema, induration or swelling, warmth 	0-7 days	
Nodule	<ul style="list-style-type: none"> Is more than 2.5 cm in diameter AND Persists for more than 1 month 	0-7 days	
Pain or Redness or Swelling	<ul style="list-style-type: none"> Pain or redness or swelling that extends past the nearest joint AND/OR Pain or redness or swelling that extends between two joints but not past either adjacent joint AND/OR Pain or redness or swelling that persists for 10 days or more 	0-48 hours	

^A The length of time between vaccine administration and onset of events is an important consideration in causality assessment. Temporal criteria guidelines in this table are generally agreed upon approximate timelines. Clinicians may report events that exceed the maximum time of onset based on their clinical judgement and their assessment findings.

Adverse Event Following Immunization	Reporting Criteria	Temporal Criteria ^A	
		Inactivated Vaccines	Live Attenuated Vaccines
Systemic Reactions			
Adenopathy/Lymphadenopathy	<ul style="list-style-type: none"> Physician-diagnosed AND Enlargement of 1 or more lymph nodes, ≥ 1.5 cm in diameter AND/OR Draining sinus over a lymph node 	0-7 days	MMR: 5-30 days Varicella: 5-42 days
Fever	<ul style="list-style-type: none"> Fever ≥ 38°C that occurs in conjunction with another reportable adverse event 	Timing in conjunction with the other reportable adverse event(s)	
Hypotonic-Hyporesponsive Episode (HHE)	<ul style="list-style-type: none"> Physician-diagnosed AND Reduced muscle tone AND Hyporesponsiveness or unresponsiveness AND Pallor or cyanosis AND Child < 2 years of age 	0-48 hours	
Parotitis	<ul style="list-style-type: none"> Physician-diagnosed parotitis following immunization with a mumps-containing vaccine 	Not Applicable	MMR: 5-30 days
Orchitis	<ul style="list-style-type: none"> Physician-diagnosed orchitis following immunization with a mumps-containing vaccine 	Not Applicable	MMR: 5-30 days
Rash	<ul style="list-style-type: none"> Inactivated vaccines: generalized rash for which medical attention is sought, when the rash is believed to be caused by the vaccine, and for which no alternative cause has been identified OR Live vaccines: an expected rash following a live vaccine that requires hospitalization 	0-7 days	MMR: 0-30 days Varicella: 0-42 days
Screaming/Persistent crying	<ul style="list-style-type: none"> Crying is continuous/unaltered AND Lasting for 3 or more hours 	0-72 hours	
Severe Vomiting/Diarrhea	<ul style="list-style-type: none"> 3 or more episodes of vomiting or diarrhea in a 24 hour period AND Symptoms are severe, i.e., projectile vomiting or explosive, watery diarrhea 	0-72 hours	0-72 hours **0-7 days for rotavirus vaccine

^A The length of time between vaccine administration and onset of events is an important consideration in causality assessment. Temporal criteria guidelines in this table are generally agreed upon approximate timelines. Clinicians may report events that exceed the maximum time of onset based on their clinical judgement and their assessment findings.

Adverse Event Following Immunization	Reporting Criteria	Temporal Criteria ^A	
		Inactivated Vaccines	Live Attenuated Vaccines
Allergic Reactions			
Anaphylaxis	<ul style="list-style-type: none"> Any event managed as anaphylaxis following immunization 	0-24 hours	
Oculo-respiratory syndrome (ORS)	<ul style="list-style-type: none"> Bilateral red eyes AND Respiratory symptoms AND Following influenza vaccine 	0-24 hours	
Other Allergic reactions	<ul style="list-style-type: none"> Skin OR Respiratory OR Gastrointestinal manifestations 	0-48 hours	
Neurological Events			
Anaesthesia/Paraesthesia	<ul style="list-style-type: none"> Anaesthesia or paraesthesia lasting 24 hours or more 	0-15 days	MMR: 0-30 days Varicella: 0-42 days
Bell's palsy	<ul style="list-style-type: none"> Physician-diagnosed Bell's palsy 	0-3 months	
Convulsion/seizure	<ul style="list-style-type: none"> Seizures (febrile or afebrile) Include temperature if febrile seizure reported 	0-72 hours	MMR: 5-30 days Varicella: 5-42 days
Encephalopathy or Encephalitis or Myelitis or Transverse myelitis or Acute Disseminated Encephalomyelitis (ADEM)	<ul style="list-style-type: none"> Physician-diagnosed encephalopathy, encephalitis, myelitis, transverse myelitis or ADEM 	0-42 days	MMR: 5-30 days Varicella: 5-42 days
Guillain-Barré syndrome (GBS)	<ul style="list-style-type: none"> Physician-diagnosed GBS 	0-56 days	
Meningitis	<ul style="list-style-type: none"> Physician-diagnosed meningitis for which no other cause has been identified 	Not applicable	MMR: 5-30 days Varicella: 5-42 days
Subacute sclerosing panencephalitis (SSPE)	<ul style="list-style-type: none"> Physician-diagnosed SSPE 	Not applicable	Up to 10 years following immunization with a measles-containing vaccine

^A The length of time between vaccine administration and onset of events is an important consideration in causality assessment. Temporal criteria guidelines in this table are generally agreed upon approximate timelines. In certain circumstances, clinicians may report events that exceed the maximum time of onset based on their clinical judgement and their assessment findings.

Adverse Event Following Immunization	Reporting Criteria	Temporal Criteria ^A	
		Inactivated Vaccines	Live Attenuated Vaccines
Vaccine-Associated Paralytic Poliomyelitis	<ul style="list-style-type: none"> Physician-diagnosed paralysis 	Not applicable	OPV: 5-30 days
Other Events of Interest			
Arthritis	<ul style="list-style-type: none"> Physician-diagnosed arthritis AND Lasting 24 hours or more 	0-30 days	MMR: 5-30 days Varicella: 5-42 days
Kawasaki Disease	<ul style="list-style-type: none"> Physician-diagnosed Kawasaki Disease. Provide documentation confirming the diagnosis. 	0-42 days	
Intussusception or hematochezia	<ul style="list-style-type: none"> Physician-diagnosed intussusception or hematochezia 	Not applicable	Rotavirus vaccine: 0-42 days
Syncope with injury	<ul style="list-style-type: none"> Syncope with injury following immunization that required hospital or urgent care services 	0-30 minutes	
Thrombocytopenia	<ul style="list-style-type: none"> Physician-diagnosed thrombocytopenia 	0-30 days	
Thrombosis/Thromboembolism	<ul style="list-style-type: none"> Physician-diagnosed AND Confirmed by imaging 	0-28 days	
Myocarditis and/ or Pericarditis	<ul style="list-style-type: none"> Physician-diagnosed Myocarditis and/or Pericarditis AND Provide documentation confirming the diagnosis 	0-28 days	
Other severe or unusual events ^B		Variable based on event	

^A The length of time between vaccine administration and onset of events is an important consideration in causality assessment. Temporal criteria guidelines in this table are generally agreed upon approximate timelines. In certain circumstances, clinicians may report events that exceed the maximum time of onset based on their clinical judgement and their assessment findings.

^B Other serious or unusual events may include those events which:

- are life threatening or result in death; require hospitalization
- result in a residual disability; are associated with a congenital malformation
- require urgent medical attention
- have:
 - not been identified previously (e.g., Oculo-Respiratory Syndrome (ORS) was first identified during the 2000/2001 influenza season), or
 - been identified before but is occurring with greater frequency in the population (e.g., extensive local reactions)
- are clusters of events: known or new events that occur in a geographic or temporal cluster (e.g., 6 in a week, or 6 in a Health Service Delivery Area) that require further assessment, even if the total number of AEFIs may not be higher than expected.

7. Local Reactions at Injection Site

7.1 Abscesses at Injection Site

Definitions⁽²⁾:

Infected abscess: a confirmed localized collection of pus in a cavity formed by the disintegration of tissue, usually caused by microorganisms that invade the tissues. The abscess may be confirmed by spontaneous or surgical drainage of material from the mass, or imaging techniques (e.g., ultrasound, CT or MRI).

Sterile abscess: an abscess whose contents are not caused by pyogenic bacteria.

Reporting Criteria:

a) Infected Abscess:

- Material from the abscess is known to be purulent (positive gram stain or culture)
OR
- There are one or more signs of localized inflammation (erythema, pain to light touch, warmth)
AND
- Evidence of improvement related to antimicrobial therapy OR
- Physician-diagnosed

b) Sterile Abscess:

Physician-diagnosed AND any of the following:

- Material from the mass is known to be non-purulent
- Absence of signs of localized inflammation (erythema, pain to light touch, warmth)
- Failure to improve on antimicrobial therapy

Discussion:

An abscess is a fluctuant (i.e., there is a wave-like motion on palpitation due to liquid content) or draining fluid – filled lesion at the injection site, with or without fever, and generally seen within 7 days of vaccine receipt. An abscess at the injection site is a rare local reaction. Contamination of multi-dose vials (re-entering vial with a used needle, improper cleaning or improper storage) can result in infection and abscess formation. Sterile abscesses are typically not accompanied by fever. Sterile abscesses are primarily associated with aluminum-adsorbed vaccines and may occur when these vaccines are injected into subcutaneous tissue instead of muscle. They are believed to be the result of irritation from components of the vaccine, especially the adjuvant. Manage abscesses with analgesics (e.g., acetaminophen, and ice to injection site). Incision and drainage of infected abscess and antimicrobials may be required.

Recommendation:

Abscesses are not a contraindication to further doses of vaccine. Use an alternate site for the next dose. Ensure aseptic technique is used, and the correct needle length is used for an intramuscular injection.

7.2 Cellulitis

Definition:

Cellulitis⁽³⁾: an acute, infectious, expanding inflammatory condition of the skin, located in subcutaneous tissue, fat, fascia or muscle at the vaccine injection site.

Reporting Criteria:

Physician-diagnosed AND

- Characterized by at least 3 of the following local signs or symptoms:
 - pain or tenderness to touch
 - erythema
 - induration or swelling
 - warmth

Laboratory culture results would confirm the diagnosis, but such results are seldom available.

Discussion:

Cellulitis is a rare adverse event following immunization. It is distinguished from the expected local reactions by its intense erythema, tenderness to light touch, presence of induration, and substantial local warmth. Cellulitis is usually caused by infection with streptococci, staphylococci, or similar organisms. It can result from bacterial contamination of the vaccine during the manufacturing process, contamination of a vaccine vial or injection equipment, or can be due to introduction of surface bacteria into the deeper layers of the skin. Injection site cellulitis is generally seen within 7 days of vaccine receipt. Cellulitis is commonly treated with antimicrobials as it is generally a bacterial infection.

Recommendation:

Cellulitis is not a contraindication to further doses of vaccine. Use an alternate site for the next injection. Ensure aseptic technique is used.

7.3 Nodule

Definition:

Nodule⁽⁴⁾: a firm, small mass of tissue at the injection site with discrete or well demarcated borders in the absence of abscess formation, erythema and warmth.

Reporting Criteria:

- Nodule is more than 2.5 cm in diameter
AND
- Nodule persists for more than 1 month

Discussion:

Nodules are mainly associated with aluminum-adsorbed vaccines, particularly if the dose is deposited subcutaneously rather than intramuscularly. Sterile nodules can take up to 1 year or more to resolve, but most commonly resolve within 2-3 months.

Recommendation:

Nodules are not a contraindication to further doses of vaccine. Use an alternate site for the next dose. Use the correct length of needle for intramuscular injections.

7.4 Pain, Redness and Swelling**Definition⁽⁴⁻⁶⁾:**

Swelling: a visible enlargement of a limb at the site of the injection(s).

Reporting Criteria:

One or more of the following:

- Pain or redness, or swelling extends past the nearest joint
- Pain or redness or swelling that extends between two joints but not past either adjacent joint
- Pain or redness, or swelling persists for 10 days or more

Discussion:

Pain, redness and swelling at the injection site are common reactions to vaccine. These reactions tend to occur within 48 hours of vaccination. The injection of foreign material into the tissues and irritation of the tissues by the process of injection can produce an inflammatory response. These local reactions are well-reported in clinical trials.

An Arthus reaction is a large, localized reaction characterized by pain, swelling, induration and edema. The reaction usually begins 2-12 hours following immunization and develops gradually over a period of hours. The reaction is due to circulating antigen-antibody complexes formed when there is a large amount of circulating antibody prior to injection of the antigen. This results in extensive swelling at the injection site which may involve the entire limb. Most Arthus reactions resolve within one week.

An Arthus reaction in a young infant is probably due to high levels of maternal antibody in the child's blood. Arthus reactions may be seen with too frequent boosters of tetanus-containing vaccines, and have been observed following repeat doses of pneumococcal polysaccharide vaccine after short intervals.

Manage pain and swelling with cold compresses at the injection site, and acetaminophen, if required. Avoid pressure on the injection site.

Recommendations:

Local reactions are not a contraindication to further doses of vaccine.

If an Arthus reaction occurs with the initial dose of the primary infant series defer subsequent doses of the same vaccine for several months to await decline of maternally-acquired antibodies. If the infant will be less than 6 months of age for the scheduled second dose, it should be deferred until 6 months of age and the third dose given 2 months later. Deferral is not necessary if the next dose of the vaccine is due when the child is ≥ 6 months of age because circulating maternal antibody will be greatly reduced.

If an Arthus reaction occurs with a tetanus-containing booster, future boosters can be spaced at longer intervals and anti-toxin levels may be monitored to determine when boosting is needed. As anti-toxin

testing is no longer routinely available, specify the reason why the test is required on the laboratory requisition.

8. Systemic Reactions

8.1 Adenopathy/Lymphadenopathy

Definitions:

Adenopathy or **lymphadenopathy** can include:

- Enlargement of one or more lymph nodes.
- Regional adenopathy: abnormal enlargement of the lymph nodes closest to the injection site (e.g., inguinal adenopathy when associated with an IM injection in the thigh, axillary adenopathy associated with an IM injection in the deltoid).
- Draining sinus over a lymph node.
- Lymphadenitis: inflammation of one or more lymph nodes, usually caused by a primary focus of infection elsewhere in the body.
- Lymphangitic streaking: painful and inflamed red streaks below the skin's surface, following the path of lymph draining from the site of infection via lymphatic vessels to regional lymph nodes.

Reporting Criteria:

Physician-diagnosed AND

- Enlargement of one or more lymph nodes, ≥ 1.5 cm in diameter AND/OR
- Draining sinus over a lymph node.

Discussion:

Live vaccines produce a low-grade infection which can include adenopathy. With any vaccine injection, if bacteria contaminate the injection site, adenitis may occur as part of the resulting infection. Adenitis in injection site-associated infections would usually occur first in the lymph nodes draining the injection site. The adjuvanted pH1N1 (2009) vaccine was known to be associated with axillary or supraclavicular lymph node tenderness.

Recommendation:

Adenopathy is not a contraindication to further doses of vaccine. Continue with further immunizations at a different injection site. Use aseptic technique.

8.2 Fever

Definition:

Fever⁽⁷⁾: elevation of temperature above the normal body temperature (37°C; 98.6°F).

Reporting Criteria:

- Fever $\geq 38^{\circ}\text{C}$ that occurs **in conjunction with** another reportable adverse event.

Discussion:

Fever is a common expected systemic reaction that generally occurs within 72 hours of immunization with inactivated vaccines. Injected protein can affect the body's heat regulation. Fever following immunization with a live vaccine may occur at a later time (e.g., commonly 5-14 days after MMR or varicella vaccines). These delayed fevers result from a low-grade non-transmissible infection produced by the live vaccine viruses.

A fever that occurs following immunization may not be due to the vaccine. Viral and bacterial illnesses are very common in children and can result in signs and symptoms similar to those which may occur following immunization. Evaluate fevers for other causes unrelated to immunization so treatment is not delayed for serious conditions. Consider intercurrent illness and other potential causes when interpreting an adverse event following immunization.

Physician evaluation is advised when:

- an infant < 3 months of age has a fever
- infants 3-12 months of age have a fever $\geq 39^{\circ}\text{C}$
- a child < 2 years has a fever lasting longer than 24-48 hours
- an older child has a fever lasting more than 72 hours, or
- there are signs of dehydration, refusal to eat food or drink, irritability, listlessness, unresponsiveness or any other worrisome signs or symptoms.

Antipyretics [e.g., acetaminophen (10-15 mg/kg/dose)] are recommended for children who develop fever following immunization. See [Appendix B – Administration of Biological Products, 16.1 Fever Management](#). Tepid sponge baths and extra fluids will also aid in fever management. Products containing acetylsalicylic acid (ASA) should **not** be given to children because of their association with Reye syndrome. See the HealthLinkBC [Health File](#).

Recommendation:

Fevers are not a contraindication to further doses of vaccine.

8.3 Hypotonic-Hyporesponsive Episode (HHE)

Definition⁽⁸⁾:

HHE: the sudden onset, in a child under 2 years of age, of reduced muscle tone, AND either hyporesponsiveness or unresponsiveness, AND either pallor or cyanosis.

Reporting Criteria:

Physician-diagnosed HHE in a child < 2 years of age.

Discussion:

With a hypotonic-hyporesponsive episode, there is an acute decrease in sensory awareness or loss of consciousness, accompanied by pallor and muscle hypotonicity. Most reported episodes occur between 1 and 12 hours after immunization. Children are initially irritable and may be febrile. They then become pale, limp, and unresponsive or hyporesponsive. Respirations are shallow and cyanosis is frequently noted. As a result, parents may report that the child was not breathing. These episodes are usually transient (lasting a few minutes) and self-limiting.

HHE has been documented to occur after immunization with diphtheria, tetanus, *Haemophilus influenzae* type b, and hepatitis B vaccines. Most reported episodes have followed administration of pertussis-containing vaccines; there has been a decline in these reports with the use of acellular pertussis vaccines.⁽⁹⁾ HHE has been observed most frequently during the primary immunization series, mainly after the first dose. The cause of these episodes is unknown but they are most consistent with fainting spells. Some HH episodes may represent atonic seizures, consisting of sudden loss of postural tone and consciousness, perhaps triggered by fever. Other cases have been confused with anaphylaxis or hypoglycemia. Follow-up of children who have had hypotonic-hyporesponsive episodes has demonstrated complete recovery without persistent neurologic or developmental defects. No treatment is necessary. If the HH episode does not resolve spontaneously, other underlying problems should be sought and ruled out or treated.

Recommendation:

HHE is not a contraindication to further doses of the same vaccine.

8.4 Parotitis**Definition:**

Parotitis: inflammation of one or both parotid salivary glands with accompanying pain and tenderness.

Reporting Criteria:

Physician-diagnosed parotitis occurring 5-30 days following immunization with a mumps-containing vaccine.

Discussion:

Parotitis is a common manifestation of mumps infection. Since the mumps vaccine is a live virus vaccine, low-grade infection following immunization can occasionally produce the same manifestation. Vaccine-associated parotitis occurs most commonly 10-14 days after vaccination. It is transient and self-limiting, and can be managed with analgesics as required and adequate fluid intake.

Recommendation:

Parotitis is not a contraindication to a future dose of a mumps-containing vaccine.

8.5 Orchitis**Definition^{(10, 11):}**

Orchitis or inflammation of the testes rarely occurs in pre-pubertal males. Primary orchitis is uncommon except with certain viral diseases, with mumps being the most common. Less frequently, enterovirus or rarely adenoviruses, varicella-zoster virus, or West Nile virus is the causative agent. Orchitis can also be caused by bacterial infections.

When caused by mumps virus, orchitis usually occurs 4-8 days after parotitis but can develop up to 6 weeks later with or without parotitis. Viral orchitis can begin gradually but onset is usually abrupt when associated with mumps and preceded by fever, chills, nausea, and lower abdominal pain. The mumps virus can be detected in the semen for 14 days and mumps RNA can be detected for up to 40 days after wild type mumps infection. Identification of the virus following vaccine is less frequent. Laboratory testing can differentiate the wild type virus from the vaccine strain mumps virus. A recent publication of 3 cases

following MMR receipt in Australia hypothesizes an immune mediated mechanism for mumps vaccine associated orchitis.

Discussion:

Mumps is a live attenuated virus vaccine therefore it is biologically plausible for orchitis to be associated with mumps vaccine. Case reports in the literature are rare.⁽¹²⁻¹⁴⁾ There are also rare reports of higher rates of orchitis following use of mumps vaccine attributable to a mutated vaccine strain⁽¹⁵⁾ or inadequately attenuated vaccine⁽¹⁶⁾, in both instances in association with the Leningrad-Zagreb strain of the vaccine.

Reporting Criteria:

Physician-diagnosed. This event is no longer reportable in its own category. If it occurs, report under “Other severe or unusual events”.

Recommendation:

A history of orchitis temporally associated with mumps vaccine is not a contraindication to further doses of the vaccine. Wild type mumps virus orchitis rarely causes infertility, even when bilateral, and infertility as a complication of mumps vaccination has not been described. Management of viral orchitis is supportive with symptomatic management of pain with analgesics and bed-rest. Corticosteroid treatment is not recommended. Early treatment of mumps orchitis with interferon- α_{2B} in a single randomized trial suggested that it may lead to earlier symptom resolution and return to normal sperm count and motility.⁽¹¹⁾

8.6 Rash

Definition⁽¹⁷⁾:

Rash: a temporary eruption of the skin.

Reporting Criteria:

- Generalized rash, for which medical attention is sought, when the rash occurs within 7 days of immunization with an inactivated vaccine, is believed to be due to the vaccine, and for which no alternative cause has been identified OR
- An expected rash following MMR (up to 30 days) or varicella vaccine (up to 42 days) that requires hospitalization.

Notes:

A rash diagnosed as hives should be reported as an allergic reaction (refer to [Section 9](#)). If consultation on a rash is planned to be sought from a secondary provider who will be unable to assess the client in person, it is recommended that photos be taken of the rash with client consent to further inform the consultation and recommendation.

Discussion:

MMR vaccine may produce a mild, non-transmissible measles-like illness which can be manifested by a generalized rash and fever. It occurs in 5-10% of persons following the first dose of MMR, usually 7-12 days (range 5-30 days) after vaccination. It is much less common following the second dose of MMR.

An erythematous, maculopapular, measles-like rash should be distinguished from a petechial rash. Petechiae are small, purplish, hemorrhagic spots on the skin that do not blanch with pressure. Petechial

rashes should be referred for consultation to determine if further doses of the vaccine should be administered (see [11.5 Thrombocytopenia](#)).

A localized varicella-like rash occurs at the injection site in 3%-5% of individuals after a first dose of varicella vaccine, and in 1% of individuals after a second dose. A similar proportion of individuals will develop a small number of generalized varicella-like papules or vesicles. Lesions usually appear within 5-26 days of immunization. A varicella-like rash is rarely transmissible.

Most rashes occurring in children, even those temporally related to immunization, are caused by intercurrent viral illness.

A generalized rash is more likely to be vaccine-associated if it is accompanied by a local reaction at the injection site. The absence of a local reaction weakens the likelihood of a relationship between the reaction and the vaccine.

Recommendation:

Rashes other than petechial rashes are not a contraindication to further doses of a vaccine.

8.7 Screaming/Persistent crying

Definition⁽¹⁸⁾:

Crying of infants and children that is continuous and unaltered.

Reporting Criteria:

- Screaming or persistent crying [continuous, unaltered (i.e., the quality of the crying does not change throughout the episode)] AND
- Onset within 72 hours of vaccine receipt and lasting for 3 or more hours

Discussion:

Crying in children is a common reaction to painful stimuli. Most often, the crying immediately following immunization is short-lived, has a familiar sound, and is viewed as normal by parents. However, parents are concerned when crying is prolonged, persistent, and high-pitched and the infant is inconsolable. Use analgesics (e.g., acetaminophen in doses of 10-15 mg/kg every 4-6 hours) as needed to control pain. Products containing acetylsalicylic acid (ASA) should **not** be given to children because of their association with Reye syndrome.

Recommendation:

Persistent crying is not a contraindication to further doses of vaccine.

8.8 Severe Vomiting/Diarrhea

Definitions:

Vomiting: ejecting stomach contents through the mouth.

Diarrhea⁽¹⁹⁾: abnormally frequent discharge of loose or watery fecal matter from the bowel.

Reporting Criteria:

- 3 or more episodes of vomiting or diarrhea in a 24 hour period AND
- Vomiting or diarrhea is severe (i.e., projectile vomiting or explosive, watery diarrhea).

Discussion:

Nausea and diarrhea have been particularly associated with oral typhoid vaccine, human diploid cell rabies vaccine (HDCV), and Japanese B encephalitis vaccine. In clinical trials, diarrhea was not more frequent in infants following receipt of rotavirus vaccines compared to placebo. Treat severe vomiting/diarrhea symptomatically to prevent dehydration and electrolyte imbalance.

Recommendation:

Severe vomiting or diarrhea is not a contraindication to further doses of a vaccine.

9. Allergic Reactions

9.1 Anaphylaxis

Definition^(20, 21):

Anaphylaxis: a rare but potentially life threatening allergic reaction. It is characterized by rapid progression of signs and symptoms and is set apart from simple allergic reactions by the simultaneous involvement of several organ systems.

Following appropriate clinical management of suspected anaphylaxis, the [Worksheet for Events Managed as Anaphylaxis Following Immunization](#) should be completed by the health care professional who observed and treated the anaphylaxis episode. The information should be added to the AEFI report in the public health information system (e.g., Panorama or PARIS) to allow the MHO/MHO delegate to assess the event. If additional information is required from the paramedic assessment and treatment received in ambulance transfer to the emergency room, this information can be requested from BC Emergency Health Services (BCEHS). To request this information, the MHO/MHO delegate should complete the [BCEHS Application for the Release of Care Records Form](#), citing the reason as “continuity of care - anaphylaxis review and decision about subsequent immunization”, and submit to patientrecords@bcehs.ca.

The Brighton Collaboration defines anaphylaxis according to diagnostic certainty, not clinical severity of the event. The highest level of diagnostic certainty, Brighton Level 1, is defined as:

- ≥ 1 major dermatological **AND**
- ≥ 1 major cardiovascular and/or 1 major respiratory and/or gastrointestinal and/or laboratory (mast cell tryptase) criterion.

[Brighton](#) offers a tool to determine the level of certainty for anaphylaxis - see Appendix 5: Anaphylaxis Data Abstraction & Interpretation Forms, Level of Certainty Algorithms and Glossary of Terms.

One of the major criteria for the Brighton case definition of anaphylaxis is elevation in mast cell tryptase. Acute elevation of serum tryptase indicates degranulation of mast cells which occurs due to an IgE-mediated mechanism. There are no point of care tests to confirm IgE mediated anaphylaxis. Thus, blood samples for serum tryptase should be taken if the diagnosis of anaphylaxis is being considered. The rise in

tryptase levels starts to be detected in serum within minutes of anaphylaxis and the optimum period for specimen collection is 30 minutes to 3 hours after the event.

Elevated serum tryptase (normal range: < 11.1 ug/L) has a low sensitivity, but a very high specificity and positive predictive value for the diagnosis of anaphylaxis. Other factors such as age, liver disease, kidney impairment, mastocytosis, myeloproliferative/myelodysplastic diseases and the presence of heterophile antibodies or rheumatoid factors can influence the serum tryptase levels.^(22, 23)

A minority of cases reported as anaphylaxis will meet Level 1 degree of certainty. This may be because when suspected anaphylaxis is managed appropriately and promptly, escalation of symptoms and progression to a severe outcome is avoided.

Anaphylaxis must be distinguished from fainting (vasovagal syncope), breath-holding spells and anxiety, which are not reportable and which, when misdiagnosed as anaphylaxis, can result in failure to complete immunization in individuals without a valid contraindication. Symptoms that are progressive or increasing in severity are more likely to represent anaphylaxis.

For management of anaphylaxis including differentiation from events such as fainting and pain reaction, see [Part 3 – Management of Anaphylaxis in a Non-Hospital Setting](#).

Reporting Criteria:

- Managed as anaphylaxis at the time of occurrence AND
- Occurs within 24 hours of immunization.

Recommendation:

A true anaphylactic reaction to a vaccine is a contraindication to receipt of further doses of the same vaccine or to a component of a vaccine. Referral to the primary health care provider for consultation with an allergist may be sought to identify the component to which the client has hypersensitivity. It is important to avoid leaving clients inadequately immunized if they unnecessarily avoid vaccines to which they are not hypersensitive. In addition, not knowing the particular component of a vaccine to which the client is allergic may pose a risk from future vaccines that contain the same component.

9.2 Oculo-respiratory Syndrome (ORS)

Definition:

ORS: the onset of bilateral red eyes and respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness or sore throat) with or without facial edema, following influenza vaccine.

Reporting Criteria:

- Bilateral red eyes AND
- Respiratory symptoms AND
- Onset within 24 hours of influenza vaccine receipt.

Recommendation:

Most people who have had ORS after a previous dose of influenza vaccine do not experience it again. The event recurs in about 5% to 34% but it is usually milder. Most people who have experienced ORS can be safely revaccinated.

When an individual has had severe ORS symptoms such as wheeze, chest tightness/discomfort, difficulty breathing or severe throat constriction/difficulty swallowing following influenza vaccine and has not received influenza vaccine since, this is considered to be a precaution to future receipt of influenza vaccine. Such individuals who wish to receive influenza vaccine should consult with their primary health care provider and Medical Health officer for an expert review to distinguish between severe ORS and any anaphylaxis risk.

9.3 Other Allergic Reactions

Discussion:

Allergic reactions constitute a spectrum, the extreme end of which is anaphylaxis. Milder forms of allergic reactions may involve only dermatologic/mucosal, respiratory or gastrointestinal systems.

An allergic reaction is an acquired hypersensitivity to an antigen that does not normally produce such a reaction. Antigen-antibody complexes stimulate the release of chemicals, such as histamine, that produce overt signs and symptoms of hypersensitivity. An allergic reaction can occur in response to a component of a vaccine in a person previously sensitized (i.e., antibodies must be present from a previous exposure to the antigen). When reported as an adverse event, enquire about history of allergies and possible exposure to other allergens during the same time period.

Allergic reactions may be limited to one system only:

- i. Skin manifestations: urticaria (hives), erythema, pruritus, or prickle sensation, and localized or generalized edema (in the deeper layers of the skin, subcutaneous tissues or mucosa lining the throat, airways and gut). Refer to [Part 3 – Management of Anaphylaxis in a Non-Hospital Setting](#) for specific management of hives and swelling **at the injection site only**.
- ii. Respiratory manifestations: sneezing, wheezing, stridor, sensation of throat closure, sore throat, rhinorrhea, hoarse voice, dry cough, tachypnea, grunting, difficulty breathing, difficulty swallowing, indrawing/retractions, chest tightness or cyanosis.
- iii. Gastrointestinal symptoms: nausea, vomiting, or abdominal pain.
- iv. Cardiovascular symptoms: tachycardia, hypotension, palpitations, confusion, loss of consciousness.⁽²⁴⁾

Practically, the vast majority of recognized 'other allergic reactions' following immunization are dermatological. Isolated gastrointestinal reactions are uncommon and/or difficult to differentiate from other causes such as gastroenteritis, and respiratory manifestations such as wheezing more commonly occur in those with a pre-existing diagnosis of asthma and are difficult to differentiate from an exacerbation of asthma. Therefore the recommendations below are based on the temporal relationship between vaccination and the onset of dermatological manifestations. The presence of hives at the injection site is considered important in the assessment of the likelihood that the event was associated with the vaccine, as an IgE mediated reaction due to the deposition of the vaccine along the needle track indicates hypersensitivity to the product component(s).

Reporting Criteria:

- Allergic reactions occurring within 48 hours of immunization.

Note: If consultation on a rash is planned to be sought from a secondary provider who will be unable to assess the client in person it is recommended that photos be taken of the rash with client consent to further inform the consultation and recommendation.

Recommendation:

1) Generalized hives occurring from 0-2 hours after immunization (cause and effect likely):

Refer to primary health care provider with a recommendation for further assessment by an allergist prior to further doses of the same vaccine or its components.

2) Hives occurring from 2-48 hours following immunization (cause and effect less likely):

Consider providing next dose of the vaccine in a physician's office or an emergency setting and observe the patient for 1-2 hours following immunization. If there is no reaction following this dose, further immunization can be given in the routine setting. If a hive-like rash reappears with this dose, particularly a generalized rash appearing within 48 hours of vaccination dose, refer to primary health care provider with a recommendation for further assessment by an allergist prior to further doses of the same vaccine or its components.

3) Hives occurring \geq 48 hours after immunization (cause and effect link unlikely):

Consider giving next vaccine dose under routine conditions. Consider other potential causes of the hives, particularly if there was no reaction at the injection site.

10. Neurological Events

10.1 Anaesthesia/Paraesthesia

Definitions:

Anaesthesia: the loss of normal feeling or sensation; numbness.

Paraesthesia: abnormal physical sensation such as tingling, burning or prickling.

Reporting Criteria:

- Anaesthesia or paraesthesia lasting 24 hours or more.
- Beginning up to 15 days following administration of inactivated vaccines, up to 30 days following MMR, or up to 42 days following varicella vaccine.

Supporting documentation of the diagnosis should be included with the adverse event report.

Discussion:

The cause of anaesthesia or paraesthesia following vaccination is often not determined. It may be related to deposition of the vaccine close to a nerve, with subsequent pressure causing symptoms. There is no specific treatment. Investigation by a neurologist should be done to rule out permanent nerve damage.

Recommendation:

If the cause is related to injection technique, avoid the site for future injections. In most cases, immunizations can continue. Proper land marking of the injection site is important.

10.2 Bell's Palsy

Definition:

Bell's palsy: a unilateral paralysis or weakness of facial muscles.

Reporting Criteria:

Physician-diagnosed Bell's palsy occurring within 3 months of immunization.

Discussion:

The cause of Bell's palsy is not clear. There is a consideration that a viral infection such as viral meningitis or the herpes virus may be linked to Bell's palsy, since these infections can cause inflammation that can damage the nerve that controls muscles on one side of the face.

Although some variation in the prevalence of Bell's palsy has been reported, it does not appear to occur in a seasonal pattern. Influenza infection does not appear to be a precipitating event for Bell's palsy.

Bell's palsy has only once been definitively linked to immunization. An intranasal inactivated influenza vaccine used only in Switzerland was removed from the market after an increase in cases of Bell's palsy was noted.⁽²⁵⁾

Recommendation:

A temporal association between vaccine receipt and Bell's palsy onset is expected to be coincidental. Bell's palsy would not be a contraindication to further doses of vaccine.

10.3 Convulsion/Seizure

Definition⁽²⁶⁾:

Seizure(s): Episode(s) of hyperactivity in the brain resulting in sudden, involuntary muscle contractions and abnormal behaviour, loss or impairment of consciousness.

Reporting Criteria:

- Seizures (febrile or afebrile) that occur within 72 hours of inactivated vaccines, 5-30 days after MMR, or 5-42 days following varicella vaccine.

Specify in the reporting whether the seizure was afebrile or febrile; if febrile, include the temperature.

Discussion:

Seizures include paroxysms of generalized tonic skeletal muscle contractions and generalized clonic jerking, usually associated with decreased level of consciousness. Seizures may last for several minutes or more.

An abrupt rise in temperature is a risk factor for febrile seizures in susceptible children. Febrile seizures are the most common seizure disorder of childhood, and are age-dependant. They are rare prior to 6 months of age and after 5 years of age, with peak onset at 14-18 months of age. Incidence in this age group approaches 2-5%, with greater risk in those with a family history. While simple febrile seizures are disturbing for the child and parents, they have a uniformly excellent prognosis without residual sequelae and remit on their own as the child ages. There are no long-term sequelae, such as permanent brain damage, associated with simple febrile seizures. Remind parents that children susceptible to febrile seizures may have a recurrence following immunization or following other events, such as viral infections. Pre-emptive treatment with antipyretics such as acetaminophen has not been shown to prevent febrile seizures in such children.

Recommendation:

Uncomplicated febrile seizures are not a contraindication to further doses of a vaccine. Refer to the primary health care provider with a recommendation for a consultation with a neurologist when the febrile seizures are multiple or prolonged (complex seizures, status epilepticus), or, when the seizures are afebrile, to rule out an underlying disorder.

10.4 Encephalopathy/Encephalitis, Myelitis/Transverse Myelitis, ADEM⁽²⁷⁾ and SSPE

10.4.1 Encephalopathy/Encephalitis

Definitions:

Encephalopathy: a term used to describe a constellation of signs and symptoms reflecting a generalized disturbance in brain function.

Encephalitis: inflammation of the brain.

Reporting Criteria:

- Encephalopathy or encephalitis diagnosed by a physician.

Include appropriate medical documentation, physicians' assessments and test results, with the adverse event report. All reported cases of this severe but rare adverse event are reviewed by the Advisory Committee on Causality Assessment.

Discussion:

Acute **encephalopathy** is the sudden onset of major neurological illness temporally linked with immunization and characterized by two of the following:

1. Severe alteration in level of consciousness or unresponsiveness, with or without generalized or focal convulsions. The symptoms must persist for more than a few hours, with failure to recover completely within 24 hours.
2. Increased intracranial pressure (as measured and diagnosed by a physician). A bulging fontanel as described by a parent to a nurse rather than observed by a physician is **not** sufficient to diagnose increased intracranial pressure. Intense crying can cause a bulging, pulsating fontanel.
3. Distinct change in behaviour or intellectual functions lasting one day or more and felt by a physician to indicate an alteration in neurological function.

Encephalitis includes central nervous system inflammation AND either > 24 hours depressed or altered consciousness with one or more signs of reduced responsiveness OR one or more signs of focal or multi-focal central nervous system abnormality.

Immunizations may very rarely lead to acute encephalitis, particularly in the setting of live-attenuated viral vaccines. The risk of encephalitic complications from viral infections (1/1000 cases of measles; 1/6000 cases of rubella) is greater than the risk following vaccination (1/1,000,000 following MMR). Encephalitis has occurred rarely following yellow fever immunization in young infants and thus this vaccine is not recommended for infants less than 9 months of age.

Recommendation:

Encephalitis/encephalopathy are not a contraindication to further vaccination. Deferral of immunization may be considered until the neurologic condition has been diagnosed or is stable. Individuals who experience encephalitis following MMR vaccine may be tested for immunity, as further immunization is not required if serologically immune. If no other cause is found and the encephalopathy is temporally related to a combination vaccine, refer to a paediatric neurologist to determine which components of the vaccine may be continued.

10.4.2 Myelitis/Transverse Myelitis

Definitions:

Myelitis: inflammation of the parenchyma of the spinal cord.

Transverse Myelitis (TM): an abrupt onset inflammatory demyelinating condition of the spinal cord that affects almost the entire thickness of the cord but spans only one or a few vertebral segments.

Both of these conditions have multiple underlying causes similar to those associated with encephalitis/ADEM, and include infectious, toxic, neoplastic, autoimmune, and metabolic etiologies but the most common are viral and post-viral, as well as multiple sclerosis or other autoimmune disease. Myelitis may occur in conjunction with encephalitis and transverse myelitis in conjunction with ADEM.

Reporting Criteria:

Physician-diagnosed transverse myelitis with no other cause identified AND

- Occurring within 6 weeks of vaccine receipt.

Supporting documentation of the diagnosis should accompany the report.

Discussion:

In a 2009 systematic review of the relationship between transverse myelitis (TM) and vaccination, 43 cases of post-vaccination TM were identified in the literature between 1970 and 2009.^(28, 29) In 73% of cases, onset was within the first month post-vaccination and the age of patients ranged from several months to 50 years. Thirteen cases followed hepatitis B vaccination, 6 MMR, 4 DTP, 4 rabies, 3 OPV, 2 influenza, 1 typhoid vaccine, 1 pertussis, 1 Japanese B encephalitis and 2 in recipients of multiple vaccines.

In its recently published safety review of a number of vaccines, the Institute of Medicine (IOM) concluded that there is evidence of TM association to several of the diseases, with rare occurrences following wild type mumps, reactivated varicella zoster, and influenza; as well, measles and rubella can cause myelitis. However, the small number of case reports of TM associated with the vaccines reviewed by the IOM did not contain sufficient evidence of mechanisms such as autoantibodies, T cells, or molecular mimicry at play in such cases. The IOM concluded that the evidence is inadequate to accept or reject a causal relationship between MMR, varicella, influenza, hepatitis A and B, HPV, DPT and meningococcal vaccines and transverse myelitis.

Recommendation:

The decision to continue immunization must be made on a case-by-case basis. All cases should be evaluated by a neurologist.⁴³

10.4.3 Acute Disseminated Encephalomyelitis (ADEM)

Definition:

ADEM: A monophasic syndrome of brain inflammation and demyelination, occurring in temporal association with an antecedent immunologic challenge, which may rarely include immunization. ADEM is distinguished from acute encephalitis by (a) a predominance of demyelinating, rather than cytotoxic injury and (b) a temporal association with a specific inciting immunogenic challenge.⁽³⁰⁾

Reporting Criteria:

Physician-diagnosed monophasic ADEM with no other cause identified. Monophasic nature of ADEM must be assessed after monitoring for 3 months from clinical nadir.

Discussion:

Clinically, ADEM may be difficult to distinguish from acute encephalitis in the early phase of the disease, presenting with global cerebral dysfunction, multifocal neurologic findings, and meningismus. The key distinguishing feature between these two conditions is the presence of acute demyelination, confirmed on MRI or by histopathology.

Various immunizations have been temporally associated with ADEM, including Japanese encephalitis, yellow fever, measles, influenza, smallpox, anthrax and others. However the only epidemiologically and pathologically proven association of an antecedent event is with antirabies vaccination using the Semple rabies vaccine [a vaccine derived from sheep/mouse brains (not used in BC)]. There has been no observed association with modern rabies vaccines. For most vaccines incidence rates are low (0.1-0.2 per 100,000 doses administered) compared to the reported 1 in 1000 incidence of post-infectious ADEM following infection with the measles virus.

Recommendation:

The decision to continue immunization must be made on a case-by-case basis. All cases should be evaluated by a neurologist.

10.4.4 Subacute Sclerosing Panencephalitis (SSPE)

Definition:

SSPE^(31, 32): a rare, degenerative central nervous system disease occurring as a late complication of measles infection (up to 10 years later).

Reporting Criteria:

Physician-diagnosed SSPE.

Discussion:

SSPE is caused by persistence of defective measles virus in the central nervous system through means that are as yet unknown.⁽³³⁾ It is characterized by behavioural and intellectual deterioration and convulsions due to inflammation of brain tissue. Seizures, blindness and dementia can occur. Remission occurs in only

4% of cases; it is otherwise fatal, and only supportive treatment exists. For vaccine-associated cases there is no temporal criterion for reporting; as with cases following infection, the occurrence would be years following immunization.

The association between natural measles infection and SSPE has led to concern that live attenuated measles vaccine virus could also cause a persistent infection of the central nervous system. Genetic sequencing of viruses from the brains of patients with SSPE including those without a history of measles disease has only identified wild type measles virus.

Some reported cases of SSPE had history of measles vaccination and lacked a history of natural measles infection. If the vaccine indeed is associated rarely with SSPE, the risk following vaccination, if it exists, is estimated to be approximately one tenth or less of that noted after natural infection (less than 1/1,000,000 persons vaccinated versus 1/100,000 cases of measles). The results of a retrospective case control study by the Centers for Disease Control and Prevention indicate that the overall effect of measles vaccination has been to protect against SSPE by preventing measles disease. There has been a dramatic decline in the incidence of SSPE since the introduction of widespread measles immunization.

Recommendation:

A diagnosis of SSPE is a contraindication to receipt of a measles-containing vaccine.

10.5 Guillain-Barré syndrome (GBS)

Definition⁽³⁴⁾:

Guillain-Barré syndrome: an illness that includes acute onset of bilateral flaccid weakness/paralysis of the limbs with decreased or absent deep tendon reflexes.

Reporting Criteria:

Physician-diagnosed GBS AND

- Occurring within 8 weeks after immunization.

Provide documentation confirming the diagnosis. GBS cases are reviewed by the Advisory Committee on Causality Assessment (ACCA).

Discussion:

Guillain-Barré syndrome is also called acute afebrile polyneuritis or acute idiopathic polyneuritis. It is a subacute, usually symmetrical ascending paralysis, with associated sensory disturbances. It can appear as a sequelae to a variety of infections after an interval of 1-8 weeks; approximately two-thirds of patients with GBS report an antecedent infectious illness, most commonly a diarrhoeal or respiratory illness, prior to the onset of neurologic signs; *Campylobacter jejuni* is the most commonly reported pathogen in adults. A maximum degree of weakness is reached from 12 hours to 28 days after onset, followed by a clinical plateau and then either improvement or death. Overall, approximately 5-15% of patients die, and continued disability after 1 year has been estimated to be seen among 20% of patients. Studies in developed countries have suggested an incidence of 1-2 per 100,000 population per year.

There is limited evidence of an association between tetanus toxoid and GBS, and oral polio vaccine and GBS, in addition to a swine influenza vaccine (1976) that is no longer in use. While cases of GBS have been reported temporally associated with other vaccines (e.g., Menactra®), there is no evidence of a causal relationship.

Recommendation:

If GBS occurs in temporal relationship to a vaccine without an alternate (e.g., infectious) cause, subsequent doses of the same vaccine should only be given if the benefits of vaccination outweigh the risk of GBS recurrence if vaccine is given. There are no contraindications to immunization in persons with a previous history of GBS unrelated to vaccination.

10.6 Meningitis

Definitions:

Meningitis: an infection or inflammation of the membranes covering the brain and spinal cord. It is characterized by sudden onset of fever, intense headache, nausea and vomiting, and pain and stiffness in the neck.

Aseptic meningitis⁽³⁵⁾: a syndrome characterized by acute onset of signs and symptoms of meningeal inflammation, cerebrospinal fluid pleocytosis and the absence of microorganisms on Gram stain and/or on routine culture.

Reporting Criteria:

Physician-diagnosed meningitis for which no other cause has been identified AND

- Occurring within 15 days of inactivated vaccines, 5-30 days following MMR, or 0-42 days following varicella vaccine.

Include medical documentation. Reports of this major, severe but rare adverse event are subsequently investigated by the Advisory Committee on Causality Assessment.

Discussion:

Measles and mumps viruses were important causative agents of aseptic meningitis before introduction of measles and mumps vaccines. Cases of aseptic meningitis have been reported after immunization with several live attenuated vaccines, including oral polio, MMR vaccine, varicella, yellow fever and smallpox. The postulated mechanism for aseptic meningitis following attenuated live virus vaccines is infection of the meninges with the vaccine virus. Such a causal relationship was established with the Urabe strain of mumps virus^(36, 37)(1 case reported per 62,000 vaccinations), which is no longer used in vaccines in Canada. There is no evidence of a causal association with the Jeryl Lynn strain of mumps used in MMR, nor with any of the other routinely used live virus vaccines. Aseptic meningitis following immunization typically resolves without sequelae.

Recommendation:

Defer further vaccines until a determination is made as to the cause of the meningitis.

10.7 Vaccine Associated Paralytic Poliomyelitis

Definition:

Paralysis: loss of muscle tone and function with or without loss of sensation.

Reporting Criteria:

Physician-diagnosed paralysis with no other cause identified AND

- Occurring within 5-30 days following OPV and lasting more than 24 hours.

Supporting documentation of the diagnosis should accompany the report.

Discussion:

Cases of paralytic poliomyelitis have been associated with oral polio vaccine (OPV). BC has used inactivated polio vaccine (IPV) exclusively since June of 1994, and OPV has not been used since that time. In Canada from 1965 through 1992, vaccine-associated paralysis occurred in recipients of OPV at a rate of 1 case per 11.7 million doses of OPV distributed, and in contacts of vaccinees at a rate of 1 case per 3.1 million doses distributed.

Recommendation:

The decision to continue immunization must be made on a case-by-case basis. All cases should be evaluated by a neurologist.

11. Other Events of Interest

11.1 Arthritis

Definitions:

Arthritis: joint inflammation, with swelling, redness and/or warmth

Arthralgia: joint pain

Reporting Criteria:

Physician-diagnosed arthritis following receipt of a rubella-containing vaccine AND

- Lasting 24 hours or longer and associated with limitation of regular activities.

Discussion:

Arthritis is usually associated with arthralgia, but arthralgia may occur without obvious arthritis. Rubella vaccine-associated arthralgia involves, in order of decreasing frequency, the joints of the fingers, knees, wrists, elbows, ankles, hips and toes. Arthritis and arthralgia can be manifestations of natural rubella infection in adults.

Arthritis and arthralgia are recognized complications of rubella immunization. Reporting transient arthralgia is not necessary.

Transient acute arthritis or arthralgia has been shown to occur 7-21 days post immunization in susceptible adolescent and adult women immunized with the RA 27/3 strain of rubella (the strain in the measles-, mumps-, rubella-containing vaccine currently available in Canada). 25% of post-pubertal females develop arthralgia, while 10% develop arthritis-like signs and symptoms. Arthritis/arthralgia can also occur in children and adolescent and adult men, but at much lower rates. Persistence or recurrence of these symptoms is rare.⁽³⁷⁾

Analgesics or anti-inflammatory medications may be used to reduce inflammation, swelling and joint pain. Products containing acetylsalicylic acid (ASA) should **not** be given to children because of their association with Reye syndrome.

Recommendation:

Transient arthritis or arthralgia is not a contraindication to a further dose of MMR vaccine. Since the joint symptoms are likely related to seroconversion, the risk following a second MMR dose is lower than that

following the first dose. It is important to offer rubella vaccine to seronegative women of childbearing age to reduce the risk of Congenital Rubella Syndrome.

11.2 Kawasaki Disease

Definition:

Kawasaki disease is an acute self-limited vasculitis of infancy and childhood that is characterized by fever, bilateral non-exudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities, rash, and cervical lymphadenopathy.⁽³⁸⁾

Reporting Criteria:

Physician-diagnosed Kawasaki disease occurring within 42 days of immunization.
Provide documentation confirming the diagnosis.

Discussion:

Etiology for Kawasaki disease (KD) is unknown. The available evidence suggests infectious and/or environmental causes as potential triggers in genetically susceptible individuals. Data suggests, the incidence of KD is tenfold higher in siblings with most cases occurring within 10 days of the index case.⁽³⁹⁾

The peak age for occurrence of KD has been 6 to 24 months which coincides with the time when children receive most of their childhood immunizations.

KD following immunization has been observed and evaluated in several studies following both inactivated and live attenuated vaccines. These studies have generally found the risk of KD to be either similar to or less than the background rate.⁽⁴⁰⁾ However, there are variations on the case definitions used for KD for these studies.⁽⁴⁰⁾ Overall, while the temporal association between immunization and KD has been highlighted in the literature, evidence for an increased risk or a causal association is lacking.⁽³⁹⁾

The treatment of KD focuses on decreasing the inflammation of the myocardium and coronary artery wall. IVIG is the primary treatment of KD and when diagnosis is established or alternative diagnoses are unlikely, IVIG plus aspirin is the treatment of choice.^(39, 40)

Recommendation:

The decision to continue immunization must be made on a case-by-case basis. All cases should be evaluated by a pediatrician.

11.3 Intussusception/Hematochezia

Definitions:

Intussusception⁽⁴¹⁾: the telescoping of one segment of the intestine with a neighbouring segment, most often the ileum into the colon, causing partial or complete intestinal obstruction. The walls of the two sections of intestine press on each other, causing irritation, swelling and eventually decreased blood flow.

Hematochezia: red blood in the stool, (described as “red currant jelly” material) which may be associated with intussusception.

Reporting Criteria:

Physician-diagnosed intussusception or hematochezia occurring within 42 days following rotavirus vaccine receipt.

Discussion:

Intussusception is an uncommon event but one that occurs at a background rate in infants. If left untreated, intussusception can cause internal bleeding, severe abdominal infection, and death of intestinal tissue. Intussusception is the most common cause of acute intestinal obstruction in infants and young children.

A rotavirus vaccine used in the United States was withdrawn from the market in 1999 because of the reported temporal association between the development of intussusception and receipt of the vaccine. New rotavirus vaccines have been licensed after undergoing large clinical trials to assess safety with regard to intussusception. Recent large scale post-licensure trials in Mexico and Brazil found an association between rotavirus vaccine and intussusception with an excess of 1 case observed among 51,000 to 68,000 vaccinated infants.⁽⁴²⁾ A study from Australia found no overall increased risk of intussusception but did find some evidence of an elevated risk following the first dose of both rotavirus vaccines within the 1-7 and 1-21 day windows.⁽⁴³⁾ Hematochezia has not been observed in association with the bovine reassortant rotavirus vaccine in use in the USA in the VAERS system, and was not observed at a higher rate in vaccine compared to placebo infants in the clinical trials for the attenuated rotavirus vaccine which is used in the BC program.

Recommendation:

Reports of intussusception following vaccination are not expected to significantly exceed the number of cases that would be seen by chance alone. Intussusception following rotavirus vaccine is a contraindication to further doses of rotavirus vaccine. Hematochezia is not considered a contraindication to further doses of rotavirus vaccine.

11.4 Syncope with Injury

Definition:

Syncope (vasovagal reaction) or fainting: a temporary unconsciousness caused by diminished blood supply to the brain.

Reporting Criteria:

- Syncope **with injury** following immunization that required hospital or urgent care services.

Discussion^{(44, 45):}

Syncope can be triggered by various stimuli, and is observed to occur following immunization, perhaps triggered by pain or emotional reaction to the immunization process itself. It happens suddenly, before, during, or after immunization. Recovery occurs within 1-2 minutes. Refer to [Part 3 – Management of Anaphylaxis in a Non-Hospital Setting](#) for signs, symptoms and management of syncope. The risk of fainting is the more common reason to keep vaccinees under observation for 15 minutes post-immunization.

Syncope with injury has been reported following HPV vaccine and H1N1 vaccine receipt. These reports include head injuries after syncope-related falls, and motor-vehicle incidents where the individual lost consciousness while driving. Immunizers should be aware of presyncopal manifestations and take appropriate measures to prevent injuries if weakness, dizziness or loss of consciousness occurs. These

events are potentially serious and may result in hospitalization, residual disability or death. They are related to the process of immunization, rather than to a specific vaccine.

Recommendation:

Syncope is not a contraindication to further immunizations.

11.5 Thrombocytopenia

Definitions⁽⁴⁶⁻⁴⁸⁾ :

Thrombocytopenia: an abnormal haematological condition in which the number of platelets is reduced to less than $150 \times 10^9/L$, accompanied by clinical signs and/or symptoms of spontaneous bleeding.

Petechiae: small, purplish, hemorrhagic spots on the skin that do not blanch with pressure.

Reporting Criteria:

Physician-diagnosed thrombocytopenia occurring within 30 days following vaccination.

Laboratory results should accompany the report.

Discussion:

Normal platelet counts are 150-450,000/mm³. Thrombocytopenia can occur in persons of all ages. Approximately 70% of cases occur following viral illnesses, often in children. It can also occur as a complication of a variety of medications. Many cases are idiopathic. Most cases in children are mild and transient, although haemorrhagic complications can occur.

The incidence of thrombocytopenia is estimated to be between 1 in 25,000 to 1 in 40,000 doses of MMR. Most cases occur following vaccination with the first dose of measles-containing vaccine; the risk of recurrence is not known, but is thought to be low. Thrombocytopenia has also been reported following other vaccines/toxoids such as diphtheria, pertussis and tetanus vaccine, and varicella.

Corticosteroids and gamma globulin may be used to treat idiopathic thrombocytopenia. Precautions should be taken, particularly for young children, to avoid the risk and complications of bleeding (e.g., precautions to avoid serious head injuries). Control of bleeding may be necessary and transfusion of platelets may be required.

Recommendations:

Children with a history of thrombocytopenia may be at increased risk for developing thrombocytopenia after MMR vaccination. Such children should generally still be immunized because the benefits of immunization outweigh the risks. The risk of thrombocytopenia following natural measles or rubella infection is greater than the risk following immunization.

Children who develop thrombocytopenia temporally related to their first dose of MMR should be assessed for immunity to measles; if the child is susceptible, discuss the benefits/risks of revaccination with the parent. If proceeding with vaccination, ensure that the parent is aware of the potential risk of recurrence, watches the child closely for development of petechiae in the 2-3 weeks post-vaccination, and is aware of the need for injury prevention.

11.6 Thrombosis and Thromboembolism

Definitions:

Thrombosis: is a localized hemostatic plug or blood clot in a blood vessel.⁽⁴⁹⁾

Thromboembolism: is a dislodged thrombus which most commonly can occur in the lungs also known as pulmonary embolism (PE). Venous thromboembolism (VTE) is the term used to refer to PE and deep vein thrombosis (DVT).

Reporting Criteria:

- Physician-diagnosed Thrombosis and/or Thromboembolism occurring within 28 days of immunization AND
- Confirmed by imaging

Discussion:

Etiology for thromboembolic events are multifactorial involving patient-related factors and underlying disease states.⁽⁴⁹⁾

VTE events are usually associated with endothelial injury. Some of the causes for endothelial injury include hypertension, inflammation, endotoxins and plaque formation.

Arterial thrombosis is usually caused by release of atherosclerosis plaque content with platelet aggregation and subsequent activation of coagulation factors contribute resulting in arterial thrombosis.

Microvascular thrombosis is usually caused by disease processes such as sepsis, disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP) and antiphospholipid syndrome (APS).

In addition, acute bacterial and viral infections can result in transient increased risk of VTE and microvascular thrombosis.

Increased risk of VTE and DVT following quadrivalent human papillomavirus (HPV4) vaccination were identified in two post-licensure monitoring studies in US, however more than 90% of these cases had other risk factors.⁽⁴⁹⁾ Following this, a self-controlled risk interval study was conducted which included 650 000 females ages 9-26. This study concluded that there was no increased risk of VTE following HPV vaccination.⁽⁴⁹⁾

Thromboembolism with thrombocytopenia known as thrombotic thrombocytopenia syndrome (TTS) has been seen following COVID-19 AstraZeneca and Johnson & Johnson vaccines with extremely low incidence.⁽⁵⁰⁾ This is an immune mediated event in which platelet-activating antibodies against PF4 results in thrombotic thrombocytopenia.⁽⁵⁰⁾ Clinically this mimics the autoimmune heparin-induced thrombocytopenia.

The histopathology of the tissue or recovery of the thrombus yields the definitive diagnosis of thrombosis and thromboembolism. Other methods of diagnosis that may be less definitive but support the diagnosis include imaging (e.g., ultrasonography with or without doppler, CT pulmonary angiography) and laboratory results (e.g., elevated D-dimer).

Treatment for these conditions would vary depending on the etiology of the event.

Recommendation:

The decision to continue immunization must be made on a case-by-case basis. All cases should be evaluated by the client's primary health care provider

11.7 Myocarditis and/or Pericarditis

Definition:

Myocarditis: inflammation of the myocardium, or heart muscle, with associated symptoms including acute chest pain or pressure, palpitations and dyspnea after exercise or lying down and without an ischemic cause.

Reporting Criteria:

Physician-diagnosed myocarditis and/or pericarditis occurring within 28 days of immunization. Supporting documentation of the diagnosis should accompany the report.

Discussion:

Pericarditis and myocarditis share similar etiologies and risk factors, and these include infectious, non-infectious and idiopathic factors.⁽⁵¹⁾ VAERS data from 1990 to 2018 found myocarditis cases following administration of a single vaccine administration to be most frequent after first and second generation smallpox vaccines (53%) and inactivated influenza vaccines (IIV) (12%). These trends were not observed with the third generation smallpox vaccines (Imvamune).⁽⁵²⁾ With introduction of mRNA vaccines during the COVID-19 pandemic, myocarditis and pericarditis were seen after vaccination and are now known to be rarely associated with mRNA vaccines.^(53, 54) Similar trends were noted for Protein Subunit COVID-19 vaccines (Novavax) and these vaccines are now known to be rarely associated with myocarditis and pericarditis.^(55, 56)

As the findings of physical examinations from myocarditis and pericarditis cases overlap with other cardiac diseases including cardiomyopathy and heart failure, it is essential for providers to complete other investigations to support a diagnosis of myocarditis and pericarditis. While histopathology is considered the gold standard for diagnosis of myocarditis, there are other diagnostic modalities that can support the diagnosis. The imaging diagnostics that can support the diagnosis of myocarditis and pericarditis include echocardiography, cardiac magnetic resonance and electrocardiography findings (e.g. ST-segment or T-wave abnormalities). The laboratory data can also support the diagnosis of myocarditis and pericarditis by measuring of myocardial injury (cardiac troponin I and T), evidence of systemic inflammation (e.g., C-reactive protein and D-dimer) and as well as other biomarkers (e.g., autoantibodies)

Most cases of myocarditis and/or pericarditis are mild in severity with hospitalized patients discharged after 4–5 days. These cases are most commonly managed with nonsteroidal anti-inflammatory drugs, however some cases received colchicine or corticosteroids.⁽⁵⁷⁾

Recommendation:

The decision to continue immunization must be made on a case-by-case basis. All cases should be evaluated by a primary health care provider or internal medicine provider.

For additional information refer to [Summary of NACI advice on vaccination with COVID-19 vaccines following myocarditis \(with or without pericarditis\)](#).

11.8 Other Severe or Unusual Events

Criteria for Reporting:

Report other severe and unusual events with a temporal association to immunization, and for which there is no other known cause, and which are not covered under the categories previously described. These must be clinically intriguing or epidemiologically interesting events and usually require medical intervention to meet the criteria for reporting. Provide all details of the event, and include all necessary documentation with the report. Do not report expected local reactions such as pain, redness, and swelling that do not meet current reporting criteria as “other severe or unusual events”.

Report any death^(58, 59) of a vaccine recipient temporally linked (within one month) to immunization, where no other clear cause of death can be established. Report fetal death that occurs following the immunization of a pregnant woman and deaths in infants which may be diagnosed as Sudden Infant Death Syndrome when the investigation has concluded. Provide autopsy report when available.

Reporting of severe or unusual events is important not only to identify a possible causal relationship with vaccination, but also to rule out the vaccine as the cause. The severity of the adverse event and the plausibility of a causal association with vaccination will determine whether further doses of the implicated vaccine will be continued.

“Other severe or unusual” events may include those events which:

are “severe”:

- are life threatening or result in death
- require hospitalization or result in a prolongation of a hospitalization
- result in a residual disability
- are associated with a congenital malformation
- require urgent medical attention

are “unusual”:

- have not been identified previously (e.g., Oculo-Respiratory Syndrome (ORS) was first identified during the 2000/2001 influenza season)
- have been identified previously but are happening with greater frequency in the population
- are clusters of events: known or new events that occur in a geographic or temporal cluster (e.g., 6 in a week, or 6 in a Health Service Delivery Area) that require further assessment, even if the total number of AEFIs may not be higher than expected.

12. Background on Adverse Event Surveillance

Post-marketing surveillance for AEFIs is an important component of all immunization programs and is conducted at all levels of the public health system including at the global level by the World Health Organization. In Canada post-marketing adverse event surveillance started in 1965 at the Laboratory Centre for Disease Control, and is now the responsibility of the Public Health Agency of Canada (PHAC) and of Health Canada, the regulatory authority for vaccines.⁽⁶⁰⁾

The safety profile of vaccines is significantly better than that of other pharmaceutical agents, however, vaccines are not entirely risk free and their safety needs to be monitored.⁽⁶¹⁾ The importance of this surveillance is further highlighted by the fact that vaccines are unique amongst pharmaceuticals as these products are intended for use in healthy people, thus the public acceptability of risk associated with

vaccines is lower than that for drugs used to treat disease and illness. Before coming to the market, vaccine safety is assessed in clinical trials which are typically industry funded. As these studies are limited in the number of subjects enrolled, they have limited ability to detect adverse events that are rare, have long onset intervals or occur in populations that were not studied.^(62, 63) These limitations can be addressed through post-marketing vaccine safety surveillance. A robust and well-rehearsed vaccine safety surveillance system can identify and investigate suspect associations of adverse events with vaccines. Action can then be taken to debunk false associations with well-founded science, modify the use or safety profile of a vaccine, or remove unsafe vaccines from the public market. Post-marketing vaccine safety surveillance is a key component in instilling confidence among both the public and health care providers about the safety of vaccines which is important to ensure uptake and ultimately disease prevention.^(64, 65)

12.1 Objectives of Surveillance

The primary objective of the AEFI surveillance system in British Columbia (BC) is the early detection of clusters or serious adverse events related to use of specific vaccines and their further investigation and response, as well as to share reports with the national vaccine safety surveillance system.

The provincial safety surveillance system seeks to capture all BC AEFIs in a single database in order to:

1. Monitor safety of marketed vaccines in Canada;
2. Identify potential signals in events that may be caused by a vaccine;
3. Identify unusually high rates of adverse events, both with individual vaccines, combination of vaccines and individual lots of vaccine;
4. Provide timely information that can be made available to potential recipients as well as health care providers so that they can weigh the risks and benefits of immunization; and
5. Identify areas that require further epidemiologic investigation and research or problems that require immediate investigation.⁽⁶⁰⁾

12.2 Regional Public Health and Health Authorities

In British Columbia a health care provider who suspects that an adverse health event in a patient under their care may have been caused by a vaccine must report it under the Public Health Act to their local medical health officer (MHO). Reportable events are entered or transmitted into the public health information system and may be referred to the medical health officer or designate for review and recommendation. Providers without access to an electronic reporting system can report using a standard report form available at [Adverse Event Following Immunization Case Report Form](#).

AEFIs identified at BC Children's Hospital through the PHAC funded Surveillance Program for the Rapid Identification and Tracking of Infectious Diseases in Kids (SPRINT-KIDS), led by University of Calgary, are reported to the BC Centre for Disease Control (BCCDC) and to the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS). BCCDC will ensure the appropriate Health Authority receives AEFI information for their residents reported by SPRINT-KIDS. Health Authorities may provide advice back to the individual and/or immunization service provider about management of the event and future immunization. Supplementary medical information (such as medical discharge summaries or pathology reports) may be requested by the MHO if the case is serious and scheduled for review by the National Advisory Committee on Causality Assessment (ACCA) or if a consultation is requested. A consultation may be requested from the Medical Director of Immunization Programs and Vaccine Preventable Diseases Service (IPVPDS) at the BCCDC.

12.3 British Columbia Centre for Disease Control (BCCDC)

Provincial AEFI data with personal identifiers removed are submitted by BCCDC to the Public Health Agency of Canada CAEFISS program twice a month. The provincial data set in Panorama is reviewed weekly for clusters and serious events using a standard algorithm. If an immunization provider becomes aware of unusual clusters of adverse events, these should be reported to the local medical health officer and to BCCDC for further investigation. If a suspect cluster is identified at the provincial level, an investigation is started and a notification may be submitted to PHAC and/or through the Canadian Network for Public Health Intelligence (CNPHI) vaccine safety alert module. Activities include case or cluster verification through collection of confirmatory data and application of the Brighton Collaboration case definition criteria, assessment of the temporal relationship to specific vaccines, and comparison to historical event reporting rates including against available administrative data. Health Authorities may request ad hoc reports from BCCDC related to the frequency or trends of AEFIs in the province if concerned about the occurrence of a specific event in their jurisdiction.

12.4 National Role in Surveillance

In Canada, AEFIs are monitored by the Centre for Immunization and Respiratory Infectious Diseases (CIRID) at the Public Health Agency of Canada using the data in the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS).⁽⁶⁶⁾ This surveillance system was renamed in 2005 from the Vaccine Associated Adverse Event Surveillance System (VAAESS) to correspond to terminology used internationally including by the World Health Organization.⁽¹⁾ AEFI reports are submitted to PHAC by the provinces and territories. In British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, Prince Edward Island, and Northwest Territories, legislation requires reporting of AEFIs. In the 3 other provinces/territories, AEFIs are reported to public health on a voluntary basis by health care providers.

From 1991 to 2024, IMPACT (Immunization Monitoring Program ACTIVE) ran active surveillance in paediatric centres across Canada. This role was transitioned to SPRINT-KIDS in 2024. SPRINT-KIDS is a pediatric hospital-based national active surveillance network for adverse events in children following immunization. This network consists of 15 pediatric hospitals across Canada, including the BC Children's Hospital. A project team at each of these hospitals uses several methods to identify children treated in emergency departments or hospitalized with a large number of symptoms or diagnoses and assesses whether an administered vaccine could be related to the event. Any events potentially related are reported to regional health authorities, through BCCDC, and to the Public Health Agency of Canada.

A revised national adverse event reporting form, available at [Reporting Adverse Events Following Immunization \(AEFI\) in Canada](#), was developed by the federal/provincial/territorial Vaccine Vigilance Working Group of the Canadian Immunization Committee and is used in provinces without a provincial form.⁽⁶⁶⁾ The national reporting guide uses information from the [Brighton Collaboration](#) for definitions of adverse events, and for levels of diagnostic certainty of events. The Brighton Collaboration is an international voluntary collaboration focussing on vaccine safety and the development of globally accepted case definitions for adverse events following immunization.

Cases meeting certain seriousness criteria are reviewed by the National Advisory Committee on Causality Assessment (ACCA). This group was formed in 1994 to review serious cases for the possibility of a causal relationship with a vaccine and identify potential signals. The committee is comprised of specialists in pediatrics, public health, epidemiology, infectious diseases, immunology, neurology, and adverse event surveillance. Cases that meet the criteria are identified from the reports that are sent in from across the country and have been reviewed by the committee using the WHO Uppsala Monitoring Centre causality

assessment criteria and the causality assessment form.^(60, 67, 68) This assessment results in a consensus of the likelihood of causality and the results of these reviews are reported back to the provinces and territories from which the report was received. The act of performing standardized causality assessment on individual case reports by an expert multidisciplinary group is very important not only in the identification of potential new or serious signals, but also to provide arm's length oversight for vaccine safety.⁽⁶⁹⁾

Market authorization holders (i.e., the vaccine industry) are required to report serious adverse events following immunization of which they become aware from any source to the Marketed Health Products Directorate (MHPD) of Health Canada. Following review the data on these events are incorporated into the online [Canada Vigilance Adverse Drug Reaction Data Base](#).

CIRID also shares AEFI data from CAEFISS with MHPD; these data are not incorporated into the Canada Vigilance Adverse Drug Reaction Data Base.

12.5 International Role in Surveillance

The World Health Organization's International Drug Monitoring Program has been operated by the Uppsala Monitoring Centre in Sweden since 1978. This program collects and aggregates case reports from over 75 countries and uses this global data set to monitor for unusual trends in adverse events.¹ The Public Health Agency of Canada (PHAC) contributes to this program as well as being represented on the WHO Global Advisory Committee on Vaccine Safety. The Global Advisory Committee on Vaccine Safety was established in 1999 to "respond promptly, efficiently, and with scientific rigor to vaccine safety issues of potential global importance".⁽⁷⁰⁾ The committee is composed of 14 members including experts from around the world in epidemiology, statistics, paediatrics, internal medicine, pharmacology and toxicology, infectious disease, public health, immunology and autoimmunity, drug regulation and safety.

The [Brighton Collaboration](#) is an international voluntary collaboration that aims to facilitate the development, evaluation, and dissemination of high-quality information about the safety of human vaccines. The primary aim of the Brighton Collaboration is to develop globally accepted and implemented standardized case definitions of adverse events following immunizations.

Valuable information about [vaccine safety](#) is also available from the US Centers for Disease Control and Prevention (CDC) Immunization Safety Office and sourced from the passive surveillance conducted in the US jointly through the CDC and the Food and Drug Administration (Vaccine Adverse Event Reporting System or [VAERS](#)) as well as specific analytic initiatives including the Vaccine Safety Datalink ([VSD](#)). These have provided evidence regarding associations of a variety of adverse events for vaccines used in both the US and Canada, and research priorities reflect information needs for Canadian immunization programs.

12.6 Future Directions

The goal is to continually strengthen and improve the provincial vaccine safety surveillance system through collaboration, training, policy, improvements in software, and expertise. Below are some initiatives that are in progress.

- Development of a regulatory framework for reporting of AEFI under the new Public Health Act
- Preparation of a regular report on BC AEFI for health care professionals and the public
- Establishment of a standard process for serious event review

- Web-based training for Public Health Nurses related to CAEFISS-related changes in reporting criteria and categories
- Testing and deployment of the new Panorama interface for reporting AEFI
- Support reporting of AEFI reporting by physicians, pharmacists, nurse practitioners, travel medicine clinic immunizers, midwives, and those employed in emergency room settings.

13. Vaccine Injury Support Program

Serious and permanent injury from vaccination is a rare occurrence. However, until 2021, Canada was the only G7 nation without a vaccine injury compensation program. The Canadian [Vaccine Injury Support Program](#) (VISP) launched in June 2021. Claimants may be eligible if they have experienced a serious and permanent injury as a result of receiving a Health Canada authorized vaccine, administered in Canada on or after December 8, 2020. ^{A, B} Financial support is also available to dependents of an individual who died after vaccination. Information on eligibility, the claims assessment process and how to apply can be found at: vaccineinjurysupport.ca.

The VISP is independent of the adverse event following immunization (AEFI) reporting and surveillance process designed to advise about future immunization and monitor vaccine safety. Information about adverse events is not shared between B.C.'s AEFI reporting system and the Vaccine Injury Support Program.

Public health and other health care professionals who become aware of individuals with residual deficits following an event that may have been caused by a vaccine or immunization should inform such individuals about the VISP program. For public health staff, this will likely occur after a Medical Health Officer has reviewed the AEFI report and made a recommendation; those most likely to be eligible for compensation would be individuals who have not made a full recovery from their event. Once a claimant has initiated a claim through VISP, they will be assigned a VISP case manager who will assist them in retrieval and submission of documentation required to support their claim. Documentation will typically come from their primary care provider or attending physician.

^A A serious and permanent injury is defined as a severe, life-threatening or life-altering injury that may require in-person hospitalization, or a prolongation of existing hospitalization, and results in persistent or significant disability or incapacity, or where the outcome is a congenital malformation or death.

^B Quebec continues to operate its own compensation program for those immunized in Quebec. Information is available at: <https://www.quebec.ca/en/health/advice-and-prevention/vaccination/vaccine-injury-compensation-program>.

14. References

1. Public Health Agency of Canada. Canadian Immunization Guide [Internet]. Evergreen ed. Part 2- Vaccine Safety: Anaphylaxis and other acute reactions following vaccination. 2023. Available from: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-2-vaccine-safety/page-4-early-vaccine-reactions-including-anaphylaxis.html>.
2. Kohl KS, Ball L, Gidudu J, Hammer SJ, Halperin S, Heath P, et al. Abscess at injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007;25(31):5821-38.
3. Halperin S, Kohl KS, Gidudu J, Ball L, Hammer SJ, Heath P, et al. Cellulitis at injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007;25(31):5803-20.
4. Kohl KS, Walop W, Gidudu J, Ball L, Halperin S, Hammer SJ, et al. Induration at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007;25(31):5839-57.
5. Gidudu J, Kohl KS, Halperin S, Hammer SJ, Heath PT, Hennig R, et al. A local reaction at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine*. 2008;26(52):6800-13.
6. Kohl KS, Walop W, Gidudu J, Ball L, Halperin S, Hammer SJ, et al. Swelling at or near injection site: Case definition and guidelines for collection, analysis and presentation of immunization safety data. *Vaccine*. 2007;25(31):5858-74.
7. Michael Marcy S, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. *Vaccine*. 2004;22(5-6):551-6.
8. Buettcher M, Heininger U, Braun M, Bonhoeffer J, Halperin S, Heijbel H, et al. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: Case definition and guidelines for data collection, analysis, and presentation. *Vaccine*. 2007;25(31):5875-81.
9. Le Saux N, Barrowman NJ, Moore DL, Whiting S, Scheifele D, Halperin S, et al. Decrease in Hospital Admissions for Febrile Seizures and Reports of Hypotonic-Hyporesponsive Episodes Presenting to Hospital Emergency Departments Since Switching to Acellular Pertussis Vaccine in Canada: A Report From IMPACT. *Pediatrics*. 2003;112(5):e348-e.
10. MacDonald NE, Bowie WR. Epididymitis, Orchitis, and Prostatitis. In: Long SSMD, Prober CGMD, Fischer MMDMPH, editors. *Principles and Practice of Pediatric Infectious Diseases*. Fifth ed 2018. p. 371-3.e1.
11. Clifford V, Wadsley J, Jenner B, Buttery JP. Mumps vaccine associated orchitis: Evidence supporting a potential immune-mediated mechanism. *Vaccine*. 2010;28(14):2671-3.
12. Abdelbaky AM, Channappa DB, Islam S. Unilateral epididymo-orchitis: a rare complication of MMR vaccine. *Annals of the Royal College of Surgeons of England*. 2008;90(4):336-7.
13. Yoshida N, Fujino M, Ota Y, Notomi T, Nakayama T. Simple differentiation method of mumps Hoshino vaccine strain from wild strains by reverse transcription loop-mediated isothermal amplification (RT-LAMP). *Vaccine*. 2007;25(7):1281-6.
14. Kuczyk MA, Denil J, Thon WF, Djamilian M, Truss M, Schlick R, et al. Orchitis following mumps vaccination in an adult. *Urologia internationalis*. 1994;53(3):179.

15. Gilliland SM, Jenkins A, Parker L, Somdach N, Pattamadilok S, Incomserb P, et al. Vaccine-related mumps infections in Thailand and the identification of a novel mutation in the mumps fusion protein. *Biologicals*. 2013;41(2):84-7.
16. Bakker W, Mathias R. Mumps caused by an inadequately attenuated measles, mumps and rubella vaccine. *Canadian journal of infectious diseases*. 2001;12(3):144-8.
17. Beigel J, Kohl KS, Khuri-Bulos N, Bravo L, Nell P, Marcy SM, et al. Rash including mucosal involvement: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007;25(31):5697-706.
18. Bonhoeffer J, Vermeer P, Halperin S, Kempe A, Music S, Shindman J, et al. Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. *Vaccine*. 2004;22(5-6):586-91.
19. Gidudu J, Sack DA, Pina M, Hudson MJ, Kohl KS, Bishop P, et al. Diarrhea: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine*. 2011;29(5):1053-71.
20. RÜGgeberg JU, Gold MS, Erlewyn-Lajeunesse M, Martin S, MÄKela M, Nell P, et al. Anaphylaxis : Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007;25(31):5675-84.
21. Gold MS, Amarasinghe A, Greenhawt M, Kelso JM, Kochhar S, Yu-Hor Thong B, et al. Anaphylaxis: Revision of the Brighton collaboration case definition. *Vaccine*. 2023;41(15):2605-14.
22. Passia E, Jandus P. Using Baseline and Peak Serum Tryptase Levels to Diagnose Anaphylaxis: a Review. *Clinical reviews in allergy & immunology*. 2020;58(3):366-76.
23. Schliemann S, Seyfarth F, Hipler U-C, Elsner P. Impact of age and heterophilic interference on the basal serum tryptase, a risk indication for anaphylaxis, in 1,092 dermatology patients. *Acta dermato-venereologica*. 2012;92(5):484-9.
24. Canadian Immunization Research Network. Managing Adverse Events Following Immunization: Resource for Public Health 2019. Available from: <https://cirnetwork.ca/publications/aefi/>.
25. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland. *New England journal of medicine* / The New England journal of medicine. 2004;350(9):896-903.
26. Bonhoeffer J, Menkes J, Gold MS, de Souza-Brito G, Fisher MC, Halsey N, et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. *Vaccine*. 2004;22(5-6):557-62.
27. Sejvar JJ, Kohl KS, Bilynsky R, Blumberg D, Cvetkovich T, Galama J, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007;25(31):5771-92.
28. Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. *Lupus*. 2009;18(13):1198-204.
29. (IOM). *Adverse Effects of Vaccines: Evidence and Causality*. Stratton K, Ford A, Rusch E, Clayton EW, editors. Washington, DC: The National Academies Press; 2012. 894 p.

30. Huynh W, Cordato DJ, Kehdi E, Masters LT, Dedousis C. Post-vaccination encephalomyelitis: Literature review and illustrative case. *Journal of clinical neuroscience*. 2008;15(12):1315-22.
31. Bellini WJ, Rota JS, Lowe LE, Katz RS, Dyken PR, Zaki SR, et al. Subacute Sclerosing Panencephalitis: More Cases of This Fatal Disease Are Prevented by Measles Immunization than Was Previously Recognized. *The Journal of infectious diseases*. 2005;192(10):1686-93.
32. Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. *International journal of epidemiology*. 2007;36(6):1334-48.
33. Stanley A, Plotkin WAO, Paul A, Offit. *Vaccines*. 6th ed: Elsevier; 2013.
34. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine*. 2011;29(3):599-612.
35. Tapiainen T, Prevots R, Griot M, Hartmann K, Heining U, Hudson M, et al. Aseptic meningitis : Case definition and guidelines for collection, analysis and presentation of immunization safety data : Brighton collaboration standardized case definitions and guidelines for adverse events following immunization (anaphylaxis, encephalitis/ADEM, aseptic meningitis, fatigue, unexplained sudden death (DIDS), rash, thrombocytopenia, cellulitis, abscess, induration, swelling, vaccinia virus adverse events, hypotonic-hyporesponsive episode). *Vaccine*. 2007;25(31):5793-802.
36. Brown EG, Furesz J, Dimock K, Yarosh W, Contreras G. Nucleotide sequence analysis of Urabe mumps vaccine strain that caused meningitis in vaccine recipients. *Vaccine*. 1991;9(11):840-2.
37. Ray P, Black S, Shinefield H, Dillon A, Schwalbe J, Holmes S, et al. Risk of Chronic Arthropathy Among Women After Rubella Vaccination. *JAMA : the journal of the American Medical Association*. 1997;278(7):551-6.
38. Phuong LK, Bonetto C, BATTERY J, Pernus YB, Chandler R, Goldenthal KL, et al. Kawasaki disease and immunisation: Standardised case definition & guidelines for data collection, analysis. *Vaccine*. 2016;34(51):6582-96.
39. David W, Kimberlin EB, Ruth Lynfield, Mark H. Sawyer. *Red Book 2021 : Report of the Committee on Infectious Diseases*: Itasca, IL: American Academy of Pediatrics; 2021. Available from: <https://search.ebscohost.com/login.aspx?direct=true&AuthType=shib&db=nlebk&AN=2939296&site=ehost-live&scope=site>.
40. Phuong LK, Bonetto C, BATTERY J, Pernus YB, Chandler R, Felicetti P, et al. Kawasaki disease and immunisation: A systematic review. *Vaccine*. 2017;35(14):1770-9.
41. Bines JE, Kohl KS, Forster J, Zanardi LR, Davis RL, Hansen J, et al. Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. *Vaccine*. 2004;22(5-6):569-74.
42. Patel MM, López-Collada VR, Bulhões MM, De Oliveira LH, Márquez AB, Flannery B, et al. Intussusception Risk and Health Benefits of Rotavirus Vaccination in Mexico and Brazil. *New England journal of medicine* / *The New England journal of medicine*. 2011;364(24):2283-92.
43. BATTERY JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, Elliott EJ, et al. Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia. *Vaccine*. 2011;29(16):3061-6.

44. Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Communicable diseases intelligence quarterly report. 2008;32(4):371.
45. Centers for Disease Control and Prevention (CDC). Syncope After Vaccination --- United States, January 2005--July 2007. 2008.
46. Rajantie J, Zeller B, Treutiger I, Rosthøj S, on behalf of the NITPwg, five national study g, et al. Vaccination associated thrombocytopenic purpura in children. Vaccine. 2007;25(10):1838-40.
47. France EK, Glanz J, Xu S, Hambidge S, Yamasaki K, Black SB, et al. Risk of Immune Thrombocytopenic Purpura After Measles-Mumps-Rubella Immunization in Children. Pediatrics (Evanston). 2008;121(3):e687-e92.
48. Sauv e LJ, Scheifele D. Do childhood vaccines cause thrombocytopenia? Paediatrics & child health. 2009;14(1):31-2.
49. Gollamudi J, Sartain SE, Navaei AH, Aneja S, Kaur Dhawan P, Tran D, et al. Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2022;40(44):6431-44.
50. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine. 2021;384(22):2092-101.
51. Sexson Tejtel SK, Munoz FM, Al-Ammouri I, Savorgnan F, Guggilla RK, Khuri-Bulos N, et al. Myocarditis and pericarditis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2022;40(10):1499-511.
52. Su JR, McNeil MM, Welsh KJ, Marquez PL, Ng C, Yan M, et al. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018. Vaccine. 2021;39(5):839-45.
53. Yih WK, Daley MF, Duffy J, Fireman B, McClure D, Nelson J, et al. A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink. Vaccine. 2023;41(3):826-35.
54. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nature medicine. 2022;28(2):410-22.
55. Mac as Saint-Gerons D, Ibarz MT, Castro JL, For s-Martos J, Tabar s-Seisdedos R. Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase. Drugs - Real World Outcomes. 2023;10(2):263-70.
56. Novavax I. NUVAXOVID™ COVID-19 Vaccine (Recombinant protein, Adjuvanted) 2022. Available from: <https://covid-vaccine.canada.ca/info/pdf/nuvaxovid-pm-en.pdf>.
57. Fenton C LA. mRNA COVID-19 vaccines are well tolerated and myopericarditis is a rare adverse event following immunisation. Drugs Ther Perspect. 2022;38(12):532-40.
58. Jorch G, Tapiainen T, Sandbu S, Schlaud M, Schwartz A, Varricchio F, et al. Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life : Case definition and guidelines for collection, analysis, and presentation of immunization safety data : Brighton collaboration standardized case definitions and guidelines for adverse events following immunization (anaphylaxis, encephalitis/ADEM,

- aseptic meningitis, fatigue, unexplained sudden death (DIDS), rash, thrombocytopenia, cellulitis, abscess, induration, swelling, vaccinia vi. Vaccine. 2007;25(31):5707-16.
59. World Health Organization. Global Manual on Surveillance of Adverse Events Following Immunization 2016. Available from: https://iris.who.int/bitstream/handle/10665/206144/9789241507769_eng.pdf?sequence=1.
60. Public Health Agency of Canada. Canadian adverse events following immunization surveillance system (CAEFISS) 2024. Available from: <https://www.canada.ca/en/public-health/services/immunization/canadian-adverse-events-following-immunization-surveillance-system-caefiss.html>.
61. Chen RT, Pool V, Takahashi H, Weniger BG, Patel B. Combination Vaccines: Postlicensure Safety Evaluation. Clinical infectious diseases. 2001;33(Supplement-4):S327-S33.
62. Ellenberg SS, Chen RT. The Complicated Task of Monitoring Vaccine Safety. Public health reports (1974). 1997;112(1):10-20.
63. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. American journal of public health (1971). 1995;85(12):1706-9.
64. Ellenberg SS, Braun MM. Monitoring the safety of vaccines: Assessing the risks. Drug safety. 2002;25(3):145-52.
65. World Health Organization. Regional Office for the Western P. Immunization safety surveillance : guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. WHO Regional Office for the Western Pacific; 1999.
66. Public Health Agency of Canada. User guide to completion and submission of the AEFI reports 2023. Available from: <https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/reporting-adverse-events-following-immunization/user-guide-completion-submission-ae-fi-reports/user-guide-completion-submission-ae-fi-reports.pdf#page=19>.
67. World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification: World Health Organization; 2019. Available from: <https://iris.who.int/handle/10665/340802>.
68. Collet JP, MacDonald N, Cashman N, Pless R. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Bulletin of the World Health Organization. 2000;78(2):178-85.
69. World Health Organization. The Uppsala Monitoring Centre – WHO Collaborating Centre for International Drug Monitoring. 2023.
70. Folb PI, Bernatowska E, Chen R, Clemens J, Doodoo ANO, Ellenberg SS, et al. A Global Perspective on Vaccine Safety and Public Health: The Global Advisory Committee on Vaccine Safety. American journal of public health (1971). 2004;94(11):1926-31.